Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

PR Newswire - Fri Mar 24, 2023

FN Media Group Presents USA News Group News Commentary

VANCOUVER, British Columbia, March 24, 2023 /PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis. According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%. Over the last year, the biotech sector has increased its efforts and delivered very optimistic data from such groups as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), CytomX Therapeutics, Inc. (NASDAQ: CTMX), BriaCell Therapeutics (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT), Relay Therapeutics (NASDAQ: RLAY), and Hologic, Inc. (NASDAQ: HOLX).

Read more at prnewswire.com